CCTG Disease Site CommitteesCCTG disease site committees discuss proposals for new studies, consider their scientific merit and feasibility, and assign priorities. Each committee is composed of representatives from centres participating in CCTG trials who communicate their centre's perspective regarding trial proposals.Committee terms of referenceEach disease site committee has a chair and an executive who review studies proposed by their respective site committees and then recommend trials for consideration to the CCTG Clinical Trials Committee.Brain Disease Site Committee >2024 Brain Committee OverviewBreast Disease Site Committee > 2024 Breast Committee OverviewGastrointestinal Disease Site Committee > 2024 Gastrointestinal Committee OverviewGenitourinary Disease Site Committee > 2024 Genitourinary Committee OverviewGynecologic Gynecologic Disease Site Committee >2024 Gynecologic Committee OverviewHead & Neck Disease Site Committee >2024 Head & Neck Committee OverviewHematologic Disease Site Committee >2024 Hematologic Committee OverviewThoracic Disease Site Committee >2024 Thoracic Committee OverviewLung CSTB Working GroupChair & Co-Chair, SIs, SCs (Lung DSC)Melanoma & Skin Disease Site Committee >2024 Melanoma & Skin Committee OverviewSarcoma Disease Site Committee > 2024 Sarcoma Committee OverviewSupportive Care Committee2024 Supportive Care Committee OverviewCCTG IND CommitteesThe IND Committee advises the Director of the CCTG IND Program on policy matters and the overall direction of new drug studies. Members are expected to represent the views of their centres regarding interest and feasibility in proposed studies.The IND Executive Committee acts to provide ongoing review of the specific program goals and priorities, as well as review and approval (or not) of specific trial proposals. Members of the Executive include the Chair of the IND Committee, Central Office staff, IND investigators, and basic scientists.2024 IND Committee Overview